Abstract
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent and well tolerated. In Brazil, the first-generation NNRTI efavirenz is included in the majority of first-line antiretroviral treatment regimens. In this study, we evaluated the effectiveness of etravirine, a new second-generation NNRTI, among patients failing antiretroviral regimens containing first-generation NNRTIs. We assessed single resistance mutations to etravirine as well as complex resistance mutations profile and discuss the potential of introducing etravirine as salvage therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkynes
-
Anti-HIV Agents / pharmacology*
-
Antiretroviral Therapy, Highly Active / methods
-
Benzoxazines / pharmacology*
-
Brazil
-
Cyclopropanes
-
Drug Resistance, Viral*
-
HIV / drug effects*
-
HIV / genetics
-
HIV / isolation & purification
-
HIV Infections / drug therapy
-
HIV Infections / virology*
-
Humans
-
Mutation, Missense
-
Nevirapine / pharmacology*
-
Nitriles
-
Prevalence
-
Pyridazines / pharmacology*
-
Pyrimidines
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Nitriles
-
Pyridazines
-
Pyrimidines
-
etravirine
-
Nevirapine
-
efavirenz